HSCS icon

Heart Test Laboratories

2.84 USD
-0.07
2.41%
At close Mar 27, 4:00 PM EDT
1 day
-2.41%
5 days
-2.07%
1 month
-20.89%
3 months
-25.46%
6 months
-45.28%
Year to date
-24.06%
1 year
-75.75%
5 years
-98.33%
10 years
-98.33%
0
Funds holding %
of 7,390 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

1.29% less ownership

Funds ownership: 1.43% [Q3] → 0.14% (-1.29%) [Q4]

50% less funds holding

Funds holding: 6 [Q3] → 3 (-3) [Q4]

91% less capital invested

Capital invested by funds: $61.9K [Q3] → $5.4K (-$56.5K) [Q4]

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$14
393%
upside
Avg. target
$14
393%
upside
High target
$14
393%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Ascendiant Capital
Lucas Ward
25% 1-year accuracy
3 / 12 met price target
393%upside
$14
Buy
Maintained
18 Mar 2025

Financial journalist opinion

Neutral
GlobeNewsWire
2 weeks ago
HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results
Southlake, TX, March 13, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (“AI”)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the third quarter fiscal 2025 ended January 31, 2025 and provided a business update.
HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results
Neutral
GlobeNewsWire
2 weeks ago
HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications
Southlake, TX, March 10, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (“AI”)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today that it has engaged Integrous Communications, a premier investor relations firm, to enhance communication channels with investors and the investment community. Under the expert guidance of Integrous Communications, HeartSciences will embark on a comprehensive investor relations program, benefiting from Integrous Communications' proven track record in collaborating with leading medical companies to develop and execute an effective investor relations program.
HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications
Neutral
GlobeNewsWire
3 months ago
HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results
Southlake, TX, Dec. 16, 2024 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the second quarter fiscal 2025 ended October 31, 2024 and provided a business update.
HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results
Neutral
GlobeNewsWire
4 months ago
HeartSciences' AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement
Southlake, TX, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that the Centers for Medicare & Medicaid Services (CMS) has included AI-ECG technology in the 2025 Hospital Outpatient Prospective Payment System (OPPS) final rule under assignment APC 5734. This approval would allow outpatient settings to receive reimbursement for HeartSciences' MyoVista® wavECGTM algorithm and MyoVista® InsightsTM low ejection fraction algorithm, upon FDA clearance. The payment rate is expected to be $125.
HeartSciences' AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement
Neutral
GlobeNewsWire
5 months ago
HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit
Southlake, TX, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc.  d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today that Company CEO Andrew Simpson has been invited to participate in the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC and hosted by M-Vest, from Tuesday October 15 to Thursday October 17, 2024.
HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit
Neutral
GlobeNewsWire
6 months ago
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results
Southlake, TX, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the first quarter fiscal 2025 ended July 31, 2024 and provided a business update.
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results
Neutral
GlobeNewsWire
6 months ago
HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission
Southlake, TX, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the close of a non-dilutive financing, with $1.9 million in net proceeds.  The unsecured loan note has an 18-month maturity date and follows the recent 12-month extension of a $500,000 loan note to September 2025.
HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission
Neutral
GlobeNewsWire
7 months ago
HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results
Southlake, TX, July 29, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the fiscal year 2024 ended April 30, 2024 and provided a business update.
HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results
Neutral
GlobeNewsWire
8 months ago
Innovation Value Institute Analysis Demonstrates HeartSciences' MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency
Southlake, TX, July 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced an analysis published by the Innovation Value Institute (IVI) titled “Introduction of AI assisted Digital Health Technology to Improve Cardiovascular Pathway Efficiency” focused on the MyoVista® wavECG™'s potential to radically improve the cardiovascular pathway efficiency.
Innovation Value Institute Analysis Demonstrates HeartSciences' MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency
Neutral
GlobeNewsWire
8 months ago
HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare
Southlake, TX, July 25, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that the MyoVista® wavECGTM has been selected by the Innovation Value Institute as a technology which can drive the radical transformation of healthcare and has been invited to demonstrate and discuss the MyoVista wavECG at the 4th Digital Health Symposium at the United Nations General Assembly to be held in New York, USA in September 2024.
HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare
Charts implemented using Lightweight Charts™